Hairy Cell Leukemia

  • H. M. Golomb


Hairy cell leukemia (HCL) is a rare disease, involving approximately 600 new patients each year in the United States. The median age at the time of diagnosis is approximately 52 years, and about one-half of the cases occur between 40 and 60 years of age, but have occurred as young as 22 and as old as 86 years of age. Men are affected more often than women by a ratio of approximately 4 to 1. There is a familial inheritance pattern in approximately 1 % of the cases with clear parent and child diagnoses of HCL. Other suggested environmental associations such as radiation or benzene exposures have been repudiated.


Minimal Residual Disease Hairy Cell Leukemia Hairy Cell Purine Analogue Benzene Exposure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677–683PubMedGoogle Scholar
  2. 2.
    Richards JM, Mick R, Latta JM et al (1990) Serum soluble interleukin-2 receptor is associated with clinical and pathological disease status in hairy cell leukemia. Blood 76: 1941–1945PubMedGoogle Scholar
  3. 3.
    Burke JS, Byrne GE Jr, Rappaport H (1974) Hairy cell leukemia (leukemic reticuloendotheliosis). I. A clinical pathologic study of 21 patients. Cancer 33:1399–1410PubMedCrossRefGoogle Scholar
  4. 4.
    Mintz U, Golomb HM (1979) Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res 39:2366–2370PubMedGoogle Scholar
  5. 5.
    Quesada JR, Reuben J, Manning JT et al (1984) Alpha interferon for the induction of remission in hairy cell leukemia. N Engl J Med 310:15–18PubMedCrossRefGoogle Scholar
  6. 6.
    Ratain MJ, Golomb HM, Bandawil RG et al (1987) Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood 69:872–877PubMedGoogle Scholar
  7. 7.
    Braylan RC, Jaffe ES, Triche TJ, Nanba K, Fowlkes BJ, Metzger H, Frank MM, Dulan MS, Yee CL, Green I, Bernard C (1978) Structural and functional properties of the “hairy” cells of leukemic reticuloendotheliosis. Cancer 41:210–227PubMedCrossRefGoogle Scholar
  8. 8.
    Spiers ASD, Parekh SJ, Bishop MD (1984) Hairy cell leukemia: induction of complete remission with Pentostatin (2′-deoxycoformycin). J Clin Oncol 2:1336–1342PubMedGoogle Scholar
  9. 9.
    Spiers ASD, Moore D, Cassileth PA et al (1987) Remissions in hairy cell leukemia with Pentostatin (2′-deoxycoformycin). N Engl J Med 316:825–830PubMedCrossRefGoogle Scholar
  10. 10.
    Kraut EH, Bouroncle BA, Grever MR (1986) Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68:1119–1122PubMedGoogle Scholar
  11. 11.
    Kraut EH, Bouroncle BA, Grever MR (1989) Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7:168–172PubMedGoogle Scholar
  12. 12.
    Grever MR, Kopecky K, Foucar MK et al (1995) Randomized comparison of pentostatin versus alpha 2a-interferon in previously untreated patients with hairy cell leukemia. An Intergroup study. J Clin Oncol 13:974–981PubMedGoogle Scholar
  13. 13.
    Golomb HM, Dodge R, Mick R, Budman D, Hutchison R, Horning S, Schiffer CA (1994) Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia 8:2037–2040PubMedGoogle Scholar
  14. 14.
    Ribeiro P, Bovaffia F, Praud P, Blanc M, Salles B, Salles G, Coiffier B (1999) Long-term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 85:65–71PubMedCrossRefGoogle Scholar
  15. 15.
    Piro LD, Carrera CJ, Carson DA et al (1990) Lasting remission in hairy cell leukemia induced by a single infusion of 2′-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMedCrossRefGoogle Scholar
  16. 16.
    Beutler E, Piro LD, Saven A et al (1991) 2-chlorodeoxyadenosine: a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymph 5:1–8CrossRefGoogle Scholar
  17. 17.
    Estey EH, Kurzrock R, Kantarjian HM et al (1991) 2-chlorodeoxyadenosine: a new anticancer agent in lymphoid malignancies. Cancer Bull 43:253–258Google Scholar
  18. 18.
    Saven A, Piro L (1994) Newer purine analogues for the treatment of hairy cell leukemia. N Engl J Med 10:691–697Google Scholar
  19. 19.
    Tallman MS, Hakimian D, Rademaker AW et al (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88:1954–1959PubMedGoogle Scholar
  20. 20.
    Ellison DJ, Sharpe RW, Robbins BA et al (1994) Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 84:4310–4315PubMedGoogle Scholar
  21. 21.
    Filleul B, Delannoy A, Ferrant A et al (1994) A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153–1156PubMedGoogle Scholar
  22. 22.
    Konwalinka G, Schirmer M, Hilbe W et al (1995) Minimal residual disease in hairy cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood Cells Mol Dis 2:142–151CrossRefGoogle Scholar
  23. 23.
    Damasio EE, Resegotti L, Masoudi B et al (1998) Five-day intermittent vs seven-day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia. Rec Prog Med 89:68–73Google Scholar
  24. 24.
    Robak T, Blasinska-Morawiec M, Blonski J et al (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience — Poland. Eur J Haematol 62:49–56PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H. M. Golomb

There are no affiliations available

Personalised recommendations